logo.png
Corbus Pharmaceuticals Reports 2019 Third Quarter Financial Results and Provides Clinical and Corporate Updates
November 07, 2019 07:05 ET | Corbus Pharmaceuticals Holdings, Inc.
Phase 3 “RESOLVE-1” study of lenabasum for treatment of systemic sclerosis on track for topline results in summer of 2020Systemic sclerosis is a rare autoimmune disease affecting ~200,000 people in...
Equillium_FullColor_RGB-300 - transparent.png
Equillium to Present at Jefferies 2019 Healthcare Conference
May 23, 2019 16:07 ET | Equillium
LA JOLLA, Calif., May 23, 2019 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop products to treat...
Equillium_FullColor_RGB-300 - transparent.png
Equillium Expands Scientific and Clinical Advisory Team
May 06, 2019 08:30 ET | Equillium
LA JOLLA, Calif., May 06, 2019 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop products to treat...
Equillium_FullColor_RGB-300 - transparent.png
Equillium to Present at Solebury Trout Class of 2018 Biotech IPO Investor Day
April 16, 2019 16:07 ET | Equillium
LA JOLLA, Calif., April 16, 2019 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology company developing treatments for severe immuno-inflammatory disorders, today announced that Bruce...
Equillium_FullColor_RGB-300 - transparent.png
Equillium Reports Fourth Quarter and Full-Year 2018 Financial Results and Recent Highlights
March 27, 2019 16:07 ET | Equillium
LA JOLLA, Calif., March 27, 2019 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology company leveraging deep understanding of immunobiology to develop products to treat severe...
Equillium_FullColor_RGB-300 - transparent.png
Equillium Announces Plan to Develop EQ001 for the Treatment of Lupus Nephritis
February 26, 2019 16:07 ET | Equillium
Clinical trial evaluating EQ001 for the treatment of refractory lupus nephritis to commence in 2H 2019 Ongoing EQ001 development programs in acute graft-versus-host disease and severe asthma remain...
Autoimmune Disease Diagnostics Market size worth USD 15 Billion by 2023: Global Market Insights Inc.
July 13, 2016 11:00 ET | Global Market Insights
Ocean View, Delaware, July 13, 2016 (GLOBE NEWSWIRE) -- Autoimmune Disease Diagnostics Market size is estimated to reach USD 15.7 billion by 2023; as per a new research report by Global Market...
S.L.E. Lupus Foundation Community-Based Program Provides Model for Patient Support
September 05, 2012 12:12 ET | S.L.E. Lupus Foundation
NEW YORK, Sept. 5, 2012 (GLOBE NEWSWIRE) -- A new paper in a special volume of the academic journal Social Work in Health Care highlights the S.L.E. Lupus Foundation as a model for how community-based...